Xiang Zhang

12PUBLICATIONS
48CO-AUTHORS
Haematological tumoursMetabolic medicineMedical infection agents (incl. prions)Molecular targetsEpidemiological modelling
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (12)

|Jun 04, 2026
Gut pathobionts translocate into liver and reshape intrahepatic microbiome to facilitate hepatocellular carcinoma.

|Dec 01, 2025
From mechanisms to management: Early detection and improved treatment of MASLD and its related hepatocellular carcinoma.

Dingwu Li, Xiang Zhang

|Jan 08, 2025
Intestinal TM6SF2 protects against metabolic dysfunction-associated steatohepatitis through the gut-liver axis.

Xiang Zhang, Harry Cheuk-Hay Lau, Suki Ha

|Dec 12, 2024
Hepatic TM6SF2 activates antitumour immunity to suppress metabolic dysfunction-associated steatotic liver disease-related hepatocellular carcinoma and boosts immunotherapy.

Yating Zhang, Mingxu Xie, Jun Wen

|Jul 01, 2024
Interplay between gut microbiome, host genetic and epigenetic modifications in MASLD and MASLD-related hepatocellular carcinoma.

Suki Ha, Vincent Wai-Sun Wong, Xiang Zhang

|May 14, 2024
Targeting squalene epoxidase restores anti-PD-1 efficacy in metabolic dysfunction-associated steatohepatitis-induced hepatocellular carcinoma.

Jun Wen, Xiang Zhang, Chi Chun Wong

Pageof 2

Frequent Collaborators

8 joint publications

Jun Yu

5 joint publications

Harry Cheuk-Hay Lau

3 joint publications

Chi Chun Wong

2 joint publications

Weixin Liu